Literature DB >> 35067116

Association of lifestyle behaviors with non-alcoholic fatty liver disease and advanced fibrosis detected by transient elastography among Hispanic/Latinos adults in the U.S.

Natalia I Heredia1, Xiaotao Zhang2, Maya Balakrishnan3, Jessica P Hwang4, Aaron P Thrift5.   

Abstract

OBJECTIVES: Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent liver disease, with the highest prevalence observed in the U.S. among Hispanic/Latino adults. While physical activity and dietary behaviors have established protective associations with NAFLD and its severity, these associations have not been well-characterized in Hispanic/Latino adults. The purpose of this study was to assess the association of lifestyle behaviors with NAFLD and advanced fibrosis in US Hispanic/Latino adults.
DESIGN: We selected all Hispanic/Latino adults from the 2017-2018 National Health and Nutrition Examination Survey (NHANES). NAFLD was defined as CAP ≥285 dB/m, and advanced fibrosis as liver stiffness measurements ≥8.6 kPa. Multivariate-adjusted logistic regression models assessed associations of physical activity and sedentary behavior (Global Physical Activity Questionnaire), as well as diet quality (Healthy Eating Index [HEI]-2015) and total energy intake (24-hour recall) with NAFLD and advanced fibrosis.
RESULTS: In Hispanic/Latino adults, the overall prevalence of NAFLD was 41.5%, while the prevalence of advanced fibrosis among those with NAFLD was 17.2%. We found that higher levels of physical activity and high diet quality were associated with lower risk of NAFLD. Compared to those reporting on average 0 metabolic equivalent (MET) hours/week of physical activity, participants reporting high levels of physical activity (≥32 MET hours/week) had 40% lower risk of NAFLD (Adjusted OR = 0.60, 95%CI 0.38, 0.93). High diet quality (HEI-2015) was associated with a 30% lower risk of NAFLD (Adjusted OR = 0.70, 95% CI 0.51, 0.97) and 72% lower risk of advanced fibrosis (Adjusted OR = 0.28, 95% CI 0.12, 0.66), as compared to those with low diet quality.
CONCLUSIONS: In this population-based study, high levels of physical activity and diet quality were associated with lower risk of NAFLD in Hispanic/Latino adults. Public health and medical professionals need to concentrate efforts on lifestyle behavior change in Hispanic/Latino adults who are at high risk for serious liver disease.

Entities:  

Keywords:  Health Eating Index; Hispanic; Latino; diet; diet quality; fatty liver; fibrosis; lifestyle behaviors; non-alcoholic fatty liver disease; physical activity; sedentary behavior

Year:  2022        PMID: 35067116      PMCID: PMC9307692          DOI: 10.1080/13557858.2022.2027883

Source DB:  PubMed          Journal:  Ethn Health        ISSN: 1355-7858            Impact factor:   2.732


  23 in total

1.  Dietary Guidelines for Americans.

Authors:  Karen B DeSalvo; Richard Olson; Kellie O Casavale
Journal:  JAMA       Date:  2016-02-02       Impact factor: 56.272

Review 2.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

Review 3.  Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.

Authors:  Leon A Adams; Quentin M Anstee; Herbert Tilg; Giovanni Targher
Journal:  Gut       Date:  2017-03-17       Impact factor: 23.059

4.  Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012.

Authors:  Donna L White; Aaron P Thrift; Fasiha Kanwal; Jessica Davila; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2016-11-23       Impact factor: 22.682

5.  Diet quality and its association with nonalcoholic fatty liver disease and all-cause and cause-specific mortality.

Authors:  Eric R Yoo; Donghee Kim; Luis M Vazquez-Montesino; Jessica A Escober; Andrew A Li; Sean P Tighe; Christopher T Fernandes; George Cholankeril; Aijaz Ahmed
Journal:  Liver Int       Date:  2020-01-27       Impact factor: 5.828

Review 6.  Nonalcoholic fatty liver disease: a systematic review.

Authors:  Mary E Rinella
Journal:  JAMA       Date:  2015-06-09       Impact factor: 56.272

7.  Acculturation and Nonalcoholic Fatty Liver Disease Risk Among Hispanics of Mexican Origin: Findings From the National Health and Nutrition Examination Survey.

Authors:  Maya Balakrishnan; Fasiha Kanwal; Hashem B El-Serag; Aaron P Thrift
Journal:  Clin Gastroenterol Hepatol       Date:  2016-10-03       Impact factor: 11.382

Review 8.  Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.

Authors:  Daniel Q Huang; Hashem B El-Serag; Rohit Loomba
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-12-21       Impact factor: 46.802

9.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.

Authors:  Stefano Romeo; Julia Kozlitina; Chao Xing; Alexander Pertsemlidis; David Cox; Len A Pennacchio; Eric Boerwinkle; Jonathan C Cohen; Helen H Hobbs
Journal:  Nat Genet       Date:  2008-09-25       Impact factor: 38.330

10.  Diet Quality Association with Nonalcoholic Fatty Liver Disease by Cirrhosis Status: The Multiethnic Cohort.

Authors:  Song-Yi Park; Mazen Noureddin; Carol Boushey; Lynne R Wilkens; Veronica W Setiawan
Journal:  Curr Dev Nutr       Date:  2020-02-20
View more
  2 in total

1.  Association between type 2 diabetes status and prevalence of liver steatosis and fibrosis among adults aged ≥ 40 years.

Authors:  Jun Chen; Piao Hu; Yanfei Wang; Zhongxin Zhu
Journal:  BMC Endocr Disord       Date:  2022-05-13       Impact factor: 3.263

2.  Clinical Factors Associated with Non-Obese Nonalcoholic Fatty Liver Disease Detected among US Adults in the NHANES 2017-2018.

Authors:  Zayd Adnan Razouki; Xiaotao Zhang; Jessica P Hwang; Natalia I Heredia
Journal:  J Clin Med       Date:  2022-07-22       Impact factor: 4.964

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.